Understanding the interplay between genomic instability, MYC dosage compensation, and the underlying interactions with the miRNA-17/92 not only sheds light on cancer pathogenesis but also highlights potential therapeutic targets to disrupt these compensatory mechanisms and impair tumor growth. The gene discussed is MYC; the disease is cancer.